共 16 条
- [1] FIXED DOSE COMBINATION (FDC) OF INDACATEROL ACETATE (IND) AND MOMETASONE FUROATE (MF) AS A MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS NOT ADEQUATELY CONTROLLED WITH INHALED CORTICOSTEROIDS AND INHALED SHORT ACTING BETA2-AGONISTS: A BUDGET IMPACT ANALISYS IN ITALYVALUE IN HEALTH, 2020, 23 : S724 - S724Mangia, P. P.Pradelli, L.Gallo, O.Ritrovato, D.Ting, B.
- [2] COST-UTILITY ANALYSIS OF FIXED DOSE COMBINATION (FDC) OF INDACATEROL ACETATE (IND) GLYCOPYRRONIUM BROMIDE (GLY) AND MOMETASONE FUROATE (MF) AS A MAINTENANCE TREATMENT IN ADULT ASTHMA PATIENTS NOT ADEQUATELY CONTROLLED WITH A MAINTENANCE COMBINATION OF A LONG-ACTING BETA2-AGONIST AND A HIGH DOSE OF AN INHALED CORTICOSTEROID WHO EXPERIENCED ONE OR MORE ASTHMA EXACERBATIONS IN THE PREVIOUS YEARVALUE IN HEALTH, 2020, 23 : S719 - S719Mangia, P. P.Pradelli, L.Gallo, O.Ritrovato, D.Gupta, S.
- [3] Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF): results from randomized clinical studiesJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB59 - AB59Buhl, RolandKerstjens, HuibNikolaev, IvanVaidya, SoniyaBartels, ChristianJain, MonishJauernig, JuergenKottakis, IoannisQian, ChenyuTillman, Hanns-Christian
- [4] Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous YearClinical Drug Investigation, 2021, 41 : 785 - 794Pier Paolo MangiaOttavio GalloDaniela RitrovatoLorenzo Pradelli
- [5] Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous YearCLINICAL DRUG INVESTIGATION, 2021, 41 (09) : 785 - 794Mangia, Pier PaoloGallo, OttavioRitrovato, DanielaPradelli, Lorenzo
- [6] Which Therapeutic Option is the Safest for the Fetus in the Treatment of Maternal Asthma: Higher Dose Inhaled Corticosteroids or Long-Acting beta2-Agonists Plus Lower Dose Inhaled Corticosteroids?PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 149 - 150Eltonsy, SherifForget, AmelieBeauchesne, Marie-FranceBlais, Lucie
- [7] Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South KoreaCURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (09) : 1597 - 1605Han, SolaKim, SiinKim, HyungtaeSuh, Hae Sun
- [8] Both once-daily (QD) and twice-daily (BID) mometasone furoate (MF) provide additional improvement in patients previously maintained on short-acting inhaled beta2-agonistsJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (01) : U4 - U4Kemp, JPStewart, GERuff, MEMurray, JJHarrison, JE
- [9] Single inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) compared with a step up of treatment with fixed-dose inhaled corticosteroid-long-acting β2-agonist maintenance with a short-acting β2-agonist as reliever in adolescents and adults with poorly controlled asthma in Colombia: a cost-utility analysisJOURNAL OF ASTHMA, 2025, 62 (03) : 500 - 507Rodriguez-Martinez, Carlos E.Sossa-Briceno, Monica P.Castro-Rodriguez, Jose A.